Clearside Biomedical Inc. Overview
Clearside Biomedical, Inc., a biopharmaceutical company, is focused on developing drug therapies for eye diseases affecting the retina and choroid. Based in Alpharetta, United States, the company operates within the Health Care sector, specifically in the Pharmaceuticals industry. Clearside Biomedical is listed on the Nasdaq stock exchange and can be accessed online at www.clearsidebio.com . The company went public with its Initial Public Offering (IPO) on June 2nd, 2016.
Financial Snapshot
As of July 15, 2025, Clearside Biomedical’s stock closed at $0.836. The company’s market capitalization stands at $68,030,000 USD. Over the past year, the stock has experienced significant fluctuations, reaching a 52-week high of $1.65 on October 8, 2024, and a 52-week low of $0.70 on April 8, 2025. The Price Earnings (P/E) ratio is currently at -2.15, indicating the company’s earnings status.
Industry Focus
Clearside Biomedical is dedicated to advancing treatments for eye diseases, with a particular emphasis on conditions affecting the retina and choroid. This focus positions the company within a niche yet critical area of the pharmaceutical industry, addressing unmet medical needs in ophthalmology.
Conclusion
Clearside Biomedical, Inc. continues to navigate the competitive landscape of the biopharmaceutical industry, focusing on innovative therapies for eye diseases. With its strategic operations and ongoing research, the company aims to make significant contributions to healthcare, particularly in the field of ophthalmology.